Natera, Inc. Common Stock (NTRA) Stock Analysis
Market Closed
Sector: Healthcare · Industry: Services-Medical Laboratories
AnalystsStrong Buy30 analystsWhat's happening with NTRA
Price History
5-Year Weekly Candlestick Chart
Profile
Strong financial health; profitability, valuation, growth and earnings quality lag behind.
How is each axis scored?
- Valuation25/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (0.2%)5/25
- P/S (23.6x)0/25
- EV/EBIT (n/a)10/25
- Growth25/100 · Weak
- Revenue CAGR (38.6%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-34.0%)0/25
- ROE (-12.8%)0/25
- Net margin (-9.1%)0/25
- Operating margin (-13.0%)0/25
- Financial Health75/100 · Strong
- Altman Z (40.42)25/25
- Current ratio (2.96)25/25
- Interest coverage (-57.8x)0/25
- Net cash / debt (Net cash)25/25
- Quality33/100 · Weak
- Piotroski F (6/9)15/25
- Beneish M (-2.02)12/25
- FCF conversion (n/a)0/25
- Margin stability (σ 19.8%)6/25
About Natera, Inc. Common Stock
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. Show more
The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Headquarters: AUSTIN, TX · Employees: 6,140 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellGift · filed 2026-09-18-945 sh2026-09-16
- SellOpen market sale · filed 2026-09-17-200 sh2026-09-16
- SellOpen market sale · filed 2026-09-17-800 sh2026-09-16
- SellOpen market sale · filed 2026-09-17-450 sh2026-09-16
- SellOpen market sale · filed 2026-09-17-1400 sh2026-09-16
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
25EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF811.7xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield0.2%C
Grade C: LowTTM FCF / Market Cap — vs own 5Y history: -16.5%–0.6% · 68th pct
P/S (TTM)23.57xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 4.0x–23.1x · highest in history
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales21.1xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio33.23xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-34.0%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-12.8%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-8.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-9.1%D
Grade D: LowNet Income / Revenue
Operating Margin-13.0%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin65.1%A
Grade A: PremiumGross Profit / Revenue
FCF Margin4.2%D
Grade D: LowFCF / Revenue
True FCF Margin-10.7%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
75B+Altman Z-Score40.42A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.96xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.11xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-57.8xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT3.1xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.05xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt13.70xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Growth
25ERevenue CAGR38.6%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Implied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue14.9%D
Grade D: HighTTM stock-based comp / TTM Revenue
Quality
10/10 Loss Years33DPiotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.02C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability19.8%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue4.3%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.96xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$7.70
Cash & short-term investments per share (Finnhub)
Book Value / Share$12.26
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$80.31M
Total debt obligations (short + long term)
Cash & Equiv.$1.10B
Cash and short-term investments
Net Debt$-1.02BA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$1.77B
Shareholders' equity (book value)
Asset / Liability3.11xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$58.95B
Current Market Capitalization
Beta1.59C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Company is effectively debt-free after netting cash.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 25, 2026
Key Insights: Natera, Inc. Common Stock (NTRA)
Piotroski F-Score of 6/9 indicates mixed fundamentals for Natera, Inc. Common Stock. Altman Z-Score of 40.42 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Revenue has compounded at roughly 39% annually — a strong growth profile. Company is effectively debt-free after netting cash.
- Interest coverage of -57.8× leaves little room for earnings shocks.
- Natera, Inc. Common Stock posted a net loss in 10 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 25/100, NTRA trades at a premium to its historical multiples.
See how NTRA ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all NTRA moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 22 | After-hours | 390.90 | +5.47% | 2.18 |
Frequently Asked Questions about NTRA
Is NTRA stock a buy right now?
PreMarketPrice's quantitative model rates Natera, Inc. Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is NTRA stock overvalued?
Natera, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 25/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Natera, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for NTRA. The Earnings section lists recent reports and updates as dates are announced.
What sector does Natera, Inc. Common Stock operate in?
Natera, Inc. Common Stock operates in the Healthcare sector, within the Services-Medical Laboratories industry. The Related Stocks section lists sector peers for comparison.
What does Natera, Inc. Common Stock do?
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology.
About Natera, Inc. Common Stock (NTRA) Stock
Natera, Inc. Common Stock (NTRA) is a US-listed stock operating in the Healthcare sector, specifically the Services-Medical Laboratories industry. Real-time pricing data for Natera, Inc. Common Stock is available on this page with a market capitalization of $59.0 billion. The financial health score for NTRA is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for NTRA stock.
NTRA Stock Analysis & Key Metrics
On PreMarketPrice, you can track Natera, Inc. Common Stock (NTRA) across multiple dimensions:
- Pre-market price & movement: Real-time NTRA stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for NTRA with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Natera, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for NTRA.
- Sector peers: Compare NTRA against 10 other healthcare stocks on key financial metrics.
Is NTRA a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Natera, Inc. Common Stock (NTRA) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Natera, Inc. Common Stock (NTRA) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.